2006/048 NICE announces Alzheimer's disease drug appeal outcome and NHS guideline to support patients and carers
NICE has today (Wednesday 11 October) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer's Disease have not been upheld. NICE will recommend to the NHS in November that donepezil, galantamine and rivastigmine should only be considered as options in the treatment of people with moderate Alzheimer's disease. Memantine is only recommended as part of clinical studies for people with moderately-severe to severe Alzheimer's disease.
|2006/048 NICE announces Alzheimer´s disease drug appeal outcome and NHS guideline to support patients and carers
11 October 2006
(41.5Kb 14sec @ 28.8Kbps)
This page was last updated: 29 September 2009